Monthly Archives: October 2010
Use of Paclitaxel for Advanced Ovarian Cancer in Clinical Practice: Analysis of 541 Patients. Results from a German Multi-centre Observational Study
Paclitaxel is one of the most common antitumour agents paclitaxel for the treatment of primary and relapsed ovarian cancer. Based on a German multicentre observational study, this article reflects the use of paclitaxe in German daily clinical practice. Patients and … Continue reading
Posted in News Tagged chemotherapy, clinical trials, outcomes, Research, science, treatment Leave a comment
Preserving the Self: The Process of Decision Making About Hereditary Breast Cancer and Ovarian Cancer Risk Reduction
Women who carry BRCA1 or BRCA2 (BRCA1/2) gene mutations have up to an 88% lifetime risk of breast cancer and up to a 65% lifetime risk of ovarian cancer. Strategies to address these risks include cancer screening and risk-reducing surgery … Continue reading
The perils of taking experimental cancer drugs
Trying a new, experimental cancer drug may offer a glimpse of hope for very sick patients, but often does more harm than good, a new study shows. Researchers said cancer doctors regularly resort to drugs still undergoing testing, as long … Continue reading
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study
Background: Ovarian cancer is the leading cause of death in women with gynecological malignancies. Brain metastases are considered an uncommon metastatic site. Only few data exist on prognostic factors for this patient collective. Patients and methods: A multicenter retrospective chart … Continue reading
Company appeals genetic patent ruling
A Salt Lake City company says it is appealing a U.S. District Court ruling invalidating its patents on naturally occurring genes. In March, U.S. District Judge Robert Sweet in New York ruled that parts of seven patents held by Myriad … Continue reading
Girls with ovarian germ-cell tumors can safely skip chemotherapy unless disease recurs, new study suggests
Researchers from Dana-Farber/Children’s Hospital Cancer Center (DF/CHCC) have found that as many as 50 percent of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a “watch and wait” strategy to determine if the follow-up treatment … Continue reading
2011 Annual Gala tickets on sale now!
For the sixth year in a row, the Ovarian Cancer National Alliance has teamed up with dozens of the most celebrated women chefs from Washington, Maryland, Virginia and West Virginia. The annual Gala highlights the best of their talents and … Continue reading
Posted in Blog Leave a comment
Congressional Briefing on ovarian cancer
The Ovarian Cancer National Alliance hosted a Congressional Briefing to address policy makers, the ovarian cancer community and the general public about the need for public awareness and federal funding for this devastating disease. The panelists provided insight, personal experiences … Continue reading
The Ovarian Cancer National Alliance recognizes Congresswoman DeLauro with Hope Award
The Ovarian Cancer National Alliance honored Congresswoman Rosa DeLauro (D-CT) with the first ever Hope Award for her tireless efforts to promote the awareness of and funding for ovarian cancer. The event was followed by a Congressional Briefing on Capitol … Continue reading
Posted in Blog Leave a comment
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel
Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy. Methods Women aged 75 years or younger with newly diagnosed stage IIB or greater ovarian cancer, Eastern Cooperative Oncology … Continue reading
